APA citiranje

Smith, M. R., Antonarakis, E. S., Ryan, C. J., Berry, W. R., Shore, N. D., Liu, G., . . . Rathkopf, D. E. (2016). Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort. Eur Urol.

Citação norma Chicago

Smith, Matthew R., et al. "Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort." Eur Urol 2016.

MLA citiranje

Smith, Matthew R., et al. "Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort." Eur Urol 2016.